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Abstract 
Background 
Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been 
calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based 
equations developed in the Modified Diet in Renal Disease (MDRD) and Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) study. Recently, new equations based either 
on cystatin C (CKD-EPI Cys) or both cystatin and creatinine (CKD-EPI mix) have been 
proposed by the CKD-EPI consortium. The aim of this study was to measure the difference in 
the prevalence of stage 3 CKD, defined as an estimated GFR less than 60 mL/min/1.73 m2, in 
a population using these four equations. 
Methods 
CKD screening was performed in the Province of Liège, Belgium. On a voluntary basis, 
people aged over 50 years have been screened. GFR was estimated by the four equations. 
Stage 3 CKD was defined as a GFR less than 60 mL/min/1.73 m2. 
Results 
The population screened consisted of 4189 people (47% were men, mean age 63 ± 7y). Their 
mean serum creatinine and plasma cystatin C levels were 0.88 ± 0.21 mg/dL and 0.85 ± 0.17 
mg/L, respectively. The prevalence of CKD in this population using the MDRD, the CKD-
EPI, the CKD-EPI Cys and the CKD-EPI mix equations was 13%, 9.8%, 4.7% and 5%, 
respectively. The prevalence of CKD was significantly higher with the creatinine-based 
(MDRD and the CKD-EPI) equations compared to the new cystatin C-based equations. 
Conclusions 
Prevalence of CKD varies strongly depending on the method used to estimate GFR. Such 
discrepancies are of importance and must be confirmed and explained by additional studies, 
notably by studies using GFR measured with a reference method. 
Trial registration 
B70720071509 
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Background 
Chronic kidney disease (CKD) is frequently presented as a major public health issue, because 
a prevalence as high as 10% has been described in the general population of Western 
Countries [1,2]. In addition, CKD is associated with a high mortality risk [3-5]. In this 
context, prevention and screening of CKD could be of importance, even if definitive proof of 
the benefits of such CKD screening is still lacking [6-8]. Disease screening requires the use 
of a diagnostic tool with high sensitivity and specificity. Measuring both glomerular filtration 
rate (GFR) and proteinuria are key elements to estimate the global function of the kidneys 
[9]. In this article, we will focus on the determination of GFR. Because measuring GFR may 
be costly and cumbersome, several authors have proposed creatinine-based equations to 
improve GFR estimation. The Modified Diet in Renal Disease (MDRD) study and the 
Chronic Kidney Disease Epidemiology Collaboration study (CKD-EPI) equations are used to 
estimate CKD prevalence in epidemiological studies [10,11]. For example, according to the 
National Health and Nutrition Examination Survey (NHANES) performed in the USA, the 
prevalence of stage 3 CKD (defined as an estimated GFR (eGFR) less than 60 mL/min/1.73 
m
2) was 6.3% and 7.8% using either the CKD-EPI or MDRD study equation, respectively 
[1,11]. However, there are several limitations to the use of serum creatinine-based equations. 
There are reasons to believe that both equations overestimate the real prevalence of CKD 
because they underestimate the measured GFR (mGFR) [12]. 
Plasma cystatin C is a relatively new marker of GFR. Cystatin C seems to have most of the 
characteristics of a good biomarker of GFR [13-15]. Several equations based on plasma 
cystatin C level have been created to estimate GFR [16]. However, these equations have been 
developed by the use of a limited sample of test subjects and have been poorly validated 
[13,15]. There is also concern because of the lack of standardized calibration for the 
measurement of the plasma level of cystatin C [17-21]. Now, a standardized calibration is 
available [22] and the CKD-EPI consortium has recently proposed equations (based on 
cystatin C alone or combined with creatinine) to better estimate GFR [23]. It is thus now 
possible to compare the prevalence of stage 3 CKD with the MDRD and CKD-EPI study 
equations to its prevalence based on the new cystatin C-based equations, namely the CKD-
EPI based on cystatin C alone (CKD-EPI Cys) and CKD-EPI based on creatinine and cystatin 
C (CKD-EPI mix). 
Methods 
This study was approved by the Ethics Committee of our University Hospital (Comité 
d’Ethique Hospitalo-Facultaire Universitaire de Liège). The Belgian registration number is 
B70720071509. This prospective study was performed in the context of the CKD screening 
program organized by the Department of Health of the Province of Liège. This province is 
one of the ten provinces in Belgium. Its area is 3862 km2 and its population in 2005 was 
1,037,161 inhabitants. The CKD screening is enabled by a medical bus that travels through 
the 84 communes of the province. Between June 2008 and March 2010, 112,000 subjects 
without any other restriction that being aged between 40 and 75 years were invited through a 
personal letter to participate in a CKD screening. All individuals wanting to voluntary 
participate had to register and make an appointment by giving a phone call to the Department 
of Health of the Province of Liège. The time slot to visit the screening bus was from 9 am to 
7.45 pm so that active working people could participate. We arbitrary limited our analysis to 
subjects older than 50 years. All patients have signed informed consent. Blood samples and 
anthropometric data were collected and a short interview was done. Between June 2008 and 
March 2010, frozen blood samples were sent to the Clinical Chemistry laboratory of the 
University of Liège where they were immediately thawed and assayed. Serum creatinine was 
measured by the IDMS traceable compensated Jaffe method (Roche Diagnostics, Mannheim, 
Germany) on Modular apparatus. Cystatin C was measured by a particle-enhanced 
nephelometric immunoassay (PENIA) on the BNII nephelometer (Siemens Healthcare 
Diagnostics, Marburg, Germany). The assay was not calibrated against the international 
certified reference material ERM-DA471/IFCC for cystatin C but values were multiplied by 
1.11 as recommended by the manufacturer (customer notification November 18, 2010) to 
convert them to ERM-DA471/IFCC–equivalent concentrations [22,24]. Our university 
laboratory is currently accredited for the ISO 15189 Standard. 
Diabetes mellitus was defined as glycosylated hemoglobin greater than 48 mmoL/moL or 
self-reported diabetes. Hypertension was defined as measured systolic blood pressure by 
oscillometric method of 140 mm Hg or greater, diastolic blood pressure of 90 mm Hg or 
greater or self-reported hypertension. Smoking status was self-reported. 
The four equations analyzed in the study are shown in (Additional file 1: Table S1). Stage 3 
CKD was defined as eGFR less than 60 mL/min/1.73 m2 [9]. 
The data were anonymously analyzed. All results are expressed as mean ± SD. The 
percentage of CKD patients obtained with the four equations was compared with the 
McNemar test (paired samples). Agreement or reliability between GFR estimations was 
assessed by Cohen’s kappa statistics to discriminate GFR greater and less than 60 
mL/min/1.73 m2 (only two possible categories) [25]. A kappa value of 0.20 or less was 
considered slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 
0.61–0.80, substantial agreement; and 0.81–1.00, almost perfect agreement. We compared the 
results of the four GFR estimations by paired sample t-test. The validity between eGFR was 
studied with estimation of the bias, SD (i.e. precision) and with a graphical approach (i.e. 
Bland et Altman) [26]. In these analyses, we have arbitrarily chosen the creatinine-based 
equation results as the reference value. Because no equation can be considered as the perfect 
reference, we have only considered the absolute bias (with neither positive nor negative sign). 
Bias between equations has been defined as the absolute mean of the differences. The SD 
around the mean reflect the dispersion of the equations. 
Because performance of the equations and epidemiology of CKD are well known to be 
influenced by age, we performed analyses according to 10 years age bracket. We also 
repeated the analyses according to gender and diabetes status. 
In subgroup analyses, we focused on discrepant results between the equations regarding the 
stage 3 CKD diagnosis (i.e. eGFR < 60 mL/min/1.73 m2). Clinical characteristics of 
discrepant subjects were compared by t-test and Chi square test. In all statistical data, we 
used p < 0.05 to determine statistical significance. All analyses were performed using 
MedCalc® (MedCalc Software, Mariakerke, Belgium). 
Results 
During the study period, 4189 people were screened (47% male and 53% women). 
Anthropometric, clinical and biological characteristics of the population are shown in Table 
1. By the paired samples t-test, four equations were all different from each other (p < 0.0001). 
Prevalence of different CKD stages is shown in Table 2. Prevalence of stage 3CKD (defined 
as eGFR < 60 mL/min/1.73 m2) when GFR was estimated by the MDRD equation study was 
13.1%. This prevalence was significantly higher than the prevalence obtained with the CKD-
EPI (9.8%, p < 0.0001), the CKD Cys (4.7%, n = 198, p < 0.0001) and the CKD-EPI mix 
(5%, n = 210, p < 0.0001) equations. Differences between the CKD-EPI equations on one 
hand and the two other cystatin C-based equations on the other hand were also very 
significant (p < 0.0001). On the contrary, no significant difference was found between the 
CKD-EPI Cys and the CKD-EPI mix equations. 
Table 1 Anthropometrical and biological description of the population 
N = 4189 Mean SD Range 
Age (years) 63 7 50-96 
% men (%) 46.7   
Weight (Kg) 75 15 31-156 
Height (cm) 167 9 102-197 
BMI (Kg/m2) 27 5 13-60 
Diabetes (%) 11.9%   
Hypertension (%) 47.2%   
Current smoking 18.2%   
Creatinine (mg/dL) 0.89 0.21  
Cystatin C (mg/L) 0.85 0.17  
MDRD (mL/min/1.73 m2) 78 17  
CKD-EPI (mL/min/1.73 m2) 81 15  
CKD-EPI Cys (mL/min/1.73 m2) 92 17  
CKD-EPI mix (mL/min/1.73 m2) 88 16  
Data are expressed as mean ± SD. Prevalence of CKD (defined as a GFR less than 60 
mL/min/1.73 m2) is expressed in %. 
Table 2 Prevalence (%) of CKD stages according to the equations used 
 MDRD CKD-EPI CKD-EPI Cys CKD-EPI Mix 
All (n = 4189) 13 9.8 4.7 5 
>90 mL/min/1.73 m2 22.1 33 63.2 48.9 
60-89 mL/min/1.73 m2 64.8 57.2 32 46.1 
30-59 mL/min/1.73 m2 12.9 9.6 4.5 4.8 
<30 mL/min/1.73 m2 0.2 0.3 0.2 0.2 
Concordance analyses 
Kappa statistics showed good agreement between the MDRD and CKD-EPI equations to 
detect stage 3 CKD (κ = 0.84). They also showed good agreement between the CKD-EPI Cys 
and the CKD-EPI mix equations (κ = 0.71). On the contrary, the kappa agreement range was 
only moderate or fair between the two creatinine-based equations and the two cystatin C-
based equations (κ between 0.32 and 0.59). All kappa results between equations are 
summarized in Table 3. 
Table 3 Kappa coefficients between the equations. 95% confidence intervals are shown 
between brackets 
 MDRD CKD-EPI CKD-EPI Cys CKD-EPI mix 
MDRD XXXXXXXXX 0.84 [0.81-0.86] 0.32 [028–0.36] 0.48 [0.44-0.53] 
CKD-EPI  XXXXXXXXX 0.39 [0.33-0.44] 0.59 [0.55-0.64] 
CKD-EPI Cys   XXXXXXXXX 0.71 [0.66-0.76] 
CKD-EPI mix    XXXXXXXXX 
The Bland and Altman analyses are given in Figure 1. Once again, because no equation can 
be considered as the perfect reference, we only considered the absolute bias. In Table 4, the 
bias (mean difference) and the SD around the bias are summarized. The larger differences are 
observed between the creatinine- and the cystatin C-based equations although differences 
between the MDRD and the CKD-EPI and between the CKD-EPI Cys and CKD-EPI mix are 
lower. 
Figure 1 Bland and Altman analysis between the MDRD study, the CKD-EPI, the CKD-
EPI Cys and the CKD-EPI mix equations. The continuous line represents the mean 
difference between measured and estimated GFR, whereas the dashed lines represent the 
limits of agreement (mean difference ± 2 SD). All values are expressed in mL/min/1.73 m2. 
Table 4 Absolute bias (mean difference) (bold) and precision (SD around the bias) 
(italic) between the equations 
 MDRD CKD-EPI CKD-EPI Cys CKD-EPI mix 
MDRD XXXXXXXXX 5.8 16.3 9.8 
CKD-EPI 3 XXXXXXXXX 14.2 7.3 
CKD-EPI Cys 14.3 11.3 XXXXXXXXX 7.2 
CKD-EPI mix 9.6 6.6 4.7 XXXXXXXXX 
All data are expressed in mL/min/1.73 m2. 
Subgroups analyses according to gender, diabetic status and age 
No difference was observed between stage 3 CKD prevalence according to gender when 
either CKD-EPI Cys or CKD-EPI mix were used (Additional file 1: Table S2). On the 
contrary, the prevalence of stage 3 CKD was significantly higher in women when the CKD-
EPI equation was used and even more when the MDRD study equation was considered. 
We also calculated the prevalence of stage 3CKD in diabetic patients. In these patients, the 
prevalence with the MDRD, CKD-EPI, CKD-EPI Cys and CKD-EPI mix were 17.1%, 
14.5%, 10.2% and 10.4%, respectively. 
In Table 5 and Figure 2, we summarized the prevalence of stage 3 CKD according to age. As 
expected, the prevalence of CKD increased with age, regardless of the equation used. The 
prevalence of CKD showed a significant difference between the two creatinine-based 
equations and the two cystatin C-based equations for all age ranges, except for those older 
than 80 years. Whatever the age range, we observed no difference between the CKD-EPI Cys 
and the CKD-EPI mix equations. On the contrary, difference of prevalence between the 
MDRD and CKD-EPI equations was not significant in those older than 70 years. 
Table 5 Prevalence of CKD according to age (age ranges of 10 years) (in %) 
 Whole (n = 
4208) 
50-59 (n = 
1455) 
60-69 (n = 
1812) 
70-79 (n = 
919) 
80-89 (n = 
21) 
MDRD 13 6 * 12.9 * 23.7 47.6 
CKD-EPI 9.8 * 3.2 * 9 * 20.8 47.6 
CKD-EPI 
Cys 
4.7 *$ 1 *$ 3.6 *$ 12.1 *$ 33.3 
CKD-EPI 
mix 
5 *$ 0.8 *$ 4.4 *$ 12.1 *$ 38.1 
*p < 0.05 compared with the MDRD, $ p < 0.05 compared with the CKD-EPI, § p < 0.05 
compared with the CKD-EPI Cys. 
Figure 2 Prevalence (in % with the 95% confidence interval) of CKD according to age 
(X axis: 10 years age range) (Y axis: percentage). 
Analysis of discrepant results 
In Table 6, we showed the percentage of patients with discrepant results (eGFR > or < 60 
mL/min/1.73 m2) according to the equation used. Discrepant results (3.3%, n = 140) were 
observed between the MDRD and the CKD-EPI equations. In these subjects, the MDRD-
based results were systematically indicating CKD whereas the CKD-EPI equation results 
were greater than 60 mL/min/1.73 m2. Comparable percentage of discrepancy (2.7%, n = 
114) was observed between the CKD-EPI Cys and the CKD-EPI mix but with these 
equations, the differences between positive and negative screening were not uniform. Indeed, 
in 45% of cases, the CKD-EPI Cys indicated stage 3 CKD whereas the CKD-EPI mix result 
was greater than 60 mL/min/1.73 m2 and the opposite was observed in 55% of cases. The 
highest percentage of discrepant results was observed between the MDRD and the CKD-EPI 
Cys equations (11.3%, n = 473). An 8% discrepancy was observed between the CKD-EPI 
and the CKD-EPI Cys and between the MDRD and the CKD-EPI mix. The percentage of 
discrepancies between CKD-EPI and CKD-EPI mix was intermediate at 5.5%. Regarding 
these last comparisons, creatinine-based equations gave positive result although cystatin-C 
based equations were reassuring for stage 3 CKD diagnosis in a majority of patients. 
Table 6 Percentage of discordant patients according to the two equations considered 
 MDRD CKD-EPI CKD-EPI Cys CKD-EPI mix 
MDRD XXXXXXXXX    
CKD-EPI 3.3% (99.98%) XXXXXXXXX   
CKD-EPI Cys 11.2% (87.1%) 8.29% (81.5%) XXXXXXXXX  
CKD-EPI mix 8.63% (96.7%) 5.58% (92.8%) 2.71% (44.7%) XXXXXXXXX 
In the brackets is the percentage of patients, among these discordant patients, yielding a 
positive result (eGFR below 60 mL/min/1.73 m2) when the equation in the column is 
considered (although the equation in the same line gives an eGFR greater than 60 
mL/min/1.73 m2). 
Table 7 summarized the possible combination of screening results. Some combinations were 
not or very rarely (n < 10) found. For example, a positive screening with the two cystatin C-
based equations, but not with the creatinine-based equations was found only in 11 subjects. 
The four equations yielded the same results (positive or negative screening) in 3702 cases 
(89%). In 131 subjects, only the MDRD equation gave a positive screening result, although 
the three other equations indicated an eGFR greater than 60 mL/min/1.73 m2. Compared to 
the whole population, these patients were more often women (23.7% versus 46.8%, 
respectively) and were lighter and shorter. In 218 subjects, both MDRD and CKD-EPI 
equations gave a positive screening result although the results were negative for CKD when 
using the CKD-EPI Cys and CKD-EPI mix equations. The mean age of these discrepant 
subjects was significantly higher compared to the whole population (67 ± 7 versus 63 ± 7 
years old, respectively). Similarly, patients with positive screening for all equations except 
CKD-EPI Cys (n = 63) were older (68 ± 5 versus 63 ± 7 years old, respectively) and more 
frequently women (28.6% versus 46.8%, respectively). Inversely, patients with a positive 
screening only for CKD-EPI Cys (n = 49) were older (68 ± 7 versus 63 ± 7 years old, 
respectively) and heavier (BMI at 30 ± 6 versus 27 ± 5 kg/m2, respectively). 
Table 7 Characteristics of the subjects in the different subgroups 
 Whole MDRD>60 MDRD<60 MDRD<60 MDRD<60 MDRD<60 MDRD>60 
CKD-EPI>60 CKD-EPI<60 CKD-EPI>60 CKD-EPI<60 CKD-EPI<60 CKD-EPI>60 
CKD-EPI Cys>60 CKD-EPI Cys<60 CKD-EPI Cys>60 CKD-EPI Cys>60 CKD-EPI Cys>60 CKD-EPI Cys<60 
CKD-EPI mix>60 CKD-EPI mix<60 CKD-EPI mix>60 CKD-EPI mix>60 CKD-EPI mix<60 CKD-EPI mix>60 
N 4189 3573 129 131 218 63 49 
Age (years) 63 ± 7 62 ± 7* 71 ± 6* 63 ± 7 67 ± 7* 68 ± 5* 68 ± 7 * 
Men (%) 46.7 48.2 48.1 23.7 * 40.8 28.6 * 46.9 
Weight (Kg) 75 ± 15 75 ± 15 80 ± 17* 72 ± 14* 75 ± 14 77 ± 12 82 ± 20* 
Height (cm) 167 ± 9 167 ± 9 166 ± 9 164 ± 9* 166 ± 9 165 ± 8 166 ± 9 
BMI (Kg/m2) 27 ± 5 27 ± 5 29 ± 5* 27 ± 4 27 ± 4 28 ± 4 30 ± 6 * 
Diabetes (%) 11.9 11.1 25.6* 8.4 11 22.2* 24.5* 
HTA (%) 47.2 45.1 72.9* 50.4 51.4 63.5* 75.5* 
HTA is hypertension. *p < 0.05 compared to the whole population. 
Discussion 
Epidemiologic studies in Western countries have shown that prevalence of stage 3 CKD, 
defined as a GFR less than 60 mL/min/1.73 m2, is about 10% in the general population 
[1,2,11,27]. But there are large differences between studies regarding the prevalence of CKD 
which can be explained not only by the population characteristics, but also by the difference 
in the method used to estimate GFR [2]. Most of the recent data have been obtained with the 
MDRD study equation using a well calibrated serum creatinine [2,28,29]. However, the use 
of this equation is not free from criticisms. We and others, have demonstrated that this 
equation tends to strongly underestimate GFR in healthy populations and, more generally, in 
patients with normal or near normal creatinine values [12,30,31]. Thus, the Levey’s group 
has recently proposed a new equation, the CKD-EPI equation, which is expected to be better 
especially in the higher GFR range (over 60 ml/min/1.73 m2). Indeed, the CKD prevalence is 
significantly lower according to the CKD-EPI equations for the present population cohort 
than if the MDRD equation is used (9.8% versus 13%). Among the patients screened, 140 
(3.3%) were classified as having stage 3 CKD with the MDRD study equation but not with 
the CKD-EPI equation. This is important from an epidemiological point of view. We have 
thus confirmed that a higher prevalence of stage 3 CKD when the MDRD equation is used 
[11,32-36]. The higher prevalence of stage 3 CKD found with the MDRD study equation 
compared to the prevalence observed with the newer CKD-EPI equation may be explained by 
the systematic underestimation of GFR obtained with this first equation, especially in women 
[12,30,35,37]. Interestingly, we confirmed that difference between the MDRD and the CKD-
EPI equations seems to decrease with age, notably in subjects older than 70 years [34-38]. 
These results may be explained by the performances of the two equations which have been 
showed to be very similar (or at least less different) in elderly patients [39]. Indeed, it has 
been shown that the MDRD equation yields systematically lower eGFR results (for a given 
age and creatinine level) than the CKD-EPI equation except in the very old patient [35]. This 
is confirmed by our own data showing that all patients presenting discrepant results between 
MDRD and CKD-EPI equations are actually positively screened only by the MDRD 
equation, except in one patient who was the oldest of the sample (96 years old). 
In their initial CKD-EPI article [11], Levey et al. have also compared prevalence of CKD in 
the NHANES study. If we consider the same definition of CKD (only based on eGFR), these 
authors have found that prevalence of CKD in the NHANES study was 10.06% with the 
CKD-EPI equation and 14.9% with the MDRD study equation (Appendix Table 9 in [11]) in 
subjects aged between 60 and 69 years. The discrepancies observed between the two 
equations are comparable to discrepancies observed in our study. 
One can conclude that the performance of the CKD-EPI equation to determine the prevalence 
of CKD in epidemiological studies is better than the MDRD study equation [11,32]. 
However, this equation is not free from criticism. The CKD-EPI notably remains dependent 
on the limitations of serum creatinine and its precision is imperfect. Cystatin C is often 
presented as a better marker of kidney function, especially because its concentration is less 
influenced by muscular mass than serum creatinine [15]. New equations based on 
standardized cystatin C have been recently proposed by the CKD-EPI consortium. These 
equations have been built and internally validated from an impressive sample (5592 subjects 
in the developing dataset and 1119 in the validation dataset). The authors demonstrated better 
performance of the equations combining creatinine and cystatin C compared to the CKD-EPI 
equation [23]. Recent studies confirmed the good performances of the two cystatin C-based 
equations in specific populations [24,40]. This better performance is also supported by the 
studies that show a better estimate of mortality risk when using cystatin C compared to 
creatinine-based equations [41,42]. 
In our population of volunteers, the prevalence of stage 3 CKD is strongly discordant using 
creatinine- or cystatin C-based equations. Indeed, if the prevalence of CKD is as high as 13% 
and 9.8% using the MDRD or the CKD-EPI study equations, the prevalence will decrease to 
5%, for the equations based on cystatin C only or on cystatin C and creatinine. Interestingly, 
the seminal study on the cystatin C-based equations published by Inker et al. showed a better 
performance of the CKD-EPI mix equation to estimate GFR [23]. In our study, we found 
however no difference in the prevalence of stage 3 CKD results between the CKD-EPI Cys or 
the CKD-EPI mix. This may be related to the way the authors calibrated the cystatin C 
measurement, which was not unquestionable. Also, the bias of the equations influences the 
epidemiologic results and we note that in the CKD-EPI study (Table 3 in [43]), bias of the 
CKD-EPI Cys is similar to the bias of the CKD-EPI mix equation in the range of interest for 
the CKD screening (i.e. around 60 mL/min/1.73 m2). 
In our cohort, when we considered the ability of each equation to detect CKD, kappa 
statistics showed very good agreement (κ = 0.84) between the CKD-EPI and the MDRD 
equations. Agreement is still acceptable, even if lower (κ = 0.71), between the CKD-EPI Cys 
and the CKD-EPI mix. However, agreement between CKD-EPI (or MDRD) and CKD-EPI 
Cys is low (0.39 and 0.32, respectively) although agreement is slightly better between CKD-
EPI (and MDRD) and the CKD-EPI mix equations (0.59 and 0.48, respectively). These 
results underlined the powerful value of each biomarker in the equations: more concordant 
results between equations based exclusively on creatinine (MDRD versus CKD-EPI), poor 
concordant results between equations based on creatinine and on cystatin C only (CKD-EPI 
or MDRD versus CKD-EPI Cys), and intermediate concordance results when the mix 
equation is compared to others. Better concordance between the CKD-EPI and the two new 
cystatin C-based equations compared to the MDRD study equation is also probably explained 
by the mathematical construction of the equation (different exponent applied to creatinine 
according to creatinine level) and by the fact that the MDRD study equation has been 
developed on a very different sample [44] although the three other equations have been 
developed from comparable cohorts [11,23]. 
Bias and precision results must be interpreted with caution in our study. Indeed, the 
systematic difference between the MDRD and the CKD-EPI equations seems low (3 
mL/min/1.73 m2). It can be suggested from Figure 1 that this bias is however very dependent 
on the GFR level. The systematic difference between the MDRD and the CKD-EPI equations 
increases with increasing GFR values especially at high values. Comparing the three CKD-
EPI equations, we also found a positive correlation between the difference in equations and 
the mean of the two equations, which means that the differences between equations slightly 
increase with eGFR levels. This correlation is however low (r2 between 0.02 and 0.04, p < 
0.001) and linear although a clear non linear relationship with a knot join-point around X = 
80 mL/min/1.73 m2 does exist when MDRD is compared to CKD-EPI and CKD-EPI Mix. 
This fact also means that discrepancies between the MDRD and the CKD-EPI are systematic 
and almost in the same direction, i.e. MDRD giving a positive screening result and CKD-EPI 
giving a negative one. Such a systematic deduction cannot be done when discrepancies are 
found between the CKD-EPI Cys and the CKD-EPI mix equations. 
The prevalence of stage 3 CKD may be higher in women if the CKD-EPI, and especially if 
the MDRD study equation is used [2,11]. Contrary to the CKD-EPI and the MDRD study 
equations, the prevalence of stage 3 CKD with the cystatin C-based equations C is the same 
in both men and women. In the absence of mGFR, this discrepancy in results according to 
gender cannot be explained. Regarding the underestimation of women’s GFR by the MDRD 
equation [30], the higher prevalence of stage 3 CKD in women must be interpreted with 
caution. Differences in prevalence of CKD according to gender observed between the three 
CKD-EPI equations deserve further studies. 
Diabetes is a well-known risk factor associated with CKD. As expected, CKD prevalence 
was higher in diabetic patients than in non-diabetic patients. Interestingly, the difference 
between the prevalences with creatinine-based versus the cystatin C-based equations appears 
less important than in the general population. Once again, in the absence of measured GFR, 
we can only describe such differences. Moreover, we must be careful in our interpretation of 
this result, as diabetic patients have also different clinical characteristics than non-diabetics, 
like a higher mean BMI. 
CKD prevalence is also greatly influenced by age. As expected, we observed an increasing 
prevalence of stage 3 CKD according to age [2,23,37,45,46]. At every age range, the 
prevalence of stage 3 CKD remains significantly lower with the CKD-EPI Cys and the CKD-
EPI mix, except in the higher age category but results must be interpreted with caution due to 
the low sample number. 
It is useful to analyze the characteristics of patients with discrepant results. Generally, 
concordant results for the 4 equations were found in 3702 subjects (88%). If we based our 
CKD definition on eGFR less than 60 mL/min/1.73 m2 with all four equations, the prevalence 
of stage 3 CKD would be 3.1%. Our first comment must be emphasized: a perfect 
concordance between all four equations does not necessarily mean that the results of these 
equations are correct. Indeed, in the absence of mGFR, it remains possible that all four 
equations misclassified the patients. The same argument must be applied in the following 
discussion on discrepant subjects. In 131 subjects, the discrepant result is the positive 
screening with the MDRD study equation. As already discussed, there is little doubt that the 
MDRD effectively underestimates GFR and thus yields a substantial proportion of false 
positive screening results. The most numerous discrepant patients are those with a positive 
screening result with the creatinine-based equations (MDRD and CKD-EPI) but with a 
negative screening result with the two cystatin C-based equations. These 218 patients are 
slightly older compared to the general population (67 ± 7 y versus 63 ± 7 y). Because mGFR 
is not really known, such a discrepancy remains difficult to explain. However, this last result 
could be interpreted in the light of recent studies suggesting that the combined creatinine and 
cystatin-C based equations better estimate GFR in the elderly subject [24,45]. Moreover, it 
must be underlined that the proportion of diabetic and hypertensive subjects was the same in 
the whole population. The positive screening result using cystatin C-based equations could 
thus be the most accurate, especially in the elderly [46]. In 63 patients, the CKD-EPI Cys was 
the only one to give a negative screening result. These subjects were slightly older and more 
often women (71.4%). On the contrary, the CKD-EPI Cys is the only equation to give a 
positive screening result in 49 subjects. These subjects were older and had a higher BMI. 
Once again, in the absence of mGFR, we can only note the discrepancies without asserting 
which equation actually gives the better results. The possible influence of body mass index 
on cystatin C levels deserves future study [47]. Further studies are actually important in these 
discrepant patients who are also more frequently hypertensive and diabetic. 
There are several limitations to our study. First, the main limitation is linked to the fact that 
we have not measured GFR with a reference method. Therefore, even if we have indirect 
arguments to affirm that the CKD-EPI and MDRD equations overestimate the prevalence of 
CKD, such an assertion is conclusive only if a reference method to measure GFR is used. In 
our cohort, we can only identify clinical characteristics of discrepant patients. In the same 
vein, our Jaffe assay has lesser precision than enzymatic assays, although IDMS traceable. 
Second, our population may not be representative of the Belgian population because only 
volunteers were included. We actually noted a higher proportion of hypertension and diabetes 
than expected in the general population. Therefore, our results are not generally applicable 
for epidemiological considerations but more of an illustration of potential discrepancies in the 
CKD epidemiology due to difference in estimating GFR [21,32]. Third, we have no data on 
the ethnicity. As the ethnicity factor for each equation is different, this could be source of 
bias. But in the Province of Liège, Caucasians are by far the dominant ethnic group. 
Therefore, it is doubtful that the differences observed in our study are due to ethnic factors. 
Fourth, as in several epidemiological studies, our subjects have been tested only one time. A 
strict definition of CKD requires that two or three samples confirm the first result after at 
least three months [9]. With this correct definition, CKD prevalence would likely still be 
lower [48-52]. Last, we have defined stage 3 CKD as a GFR less than 60 mL/min/1.73 m2. 
The definition of CKD is however subject to debate and we have recently questioned this 
definition, notably in elderly population [31,37,46]. 
Conclusions 
The present study has illustrated large discrepancies for the prevalence of stage 3 CKD 
according to the biomarker used to estimate the GFR. Moving from strictly creatinine-based 
equations (MDRD or CKD-EPI) to cystatin C-based or combined equations will decrease 
prevalence of stage 3 CKD by half, which is highly significant from an epidemiological point 
of view. Additional studies are thus necessary before asserting we know the true prevalence 
of CKD in the general population. 
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